Manmath Patekar

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

Journal: The New England journal of medicine

Published: June 03, 2026

Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria.

Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria.

Journal: Clinical and translational science

Published: March 13, 2026

Efficacy and safety of canakinumab in patients with adult-onset Still's disease: Results from an open-label phase III study in Japan.

Efficacy and safety of canakinumab in patients with adult-onset Still's disease: Results from an open-label phase III study in Japan.

Journal: Modern rheumatology

Published: November 27, 2025

Ligelizumab use for chronic spontaneous urticaria - Authors' reply.

Ligelizumab use for chronic spontaneous urticaria - Authors' reply.

Journal: Lancet (London, England)

Published: June 04, 2025

Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria.

Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria.

Journal: Allergy

Published: April 15, 2025

Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria.

Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria.

Journal: CPT: pharmacometrics & systems pharmacology

Published: November 29, 2024

Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.

Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.

Journal: Pharmaceutics

Published: July 10, 2023

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.

Journal: American journal of clinical dermatology

Published: April 03, 2023

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.

Journal: Lancet (London, England)

Published: January 24, 2023

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.

Journal: Paediatric drugs

Published: April 03, 2022

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.

Journal: Chinese medical journal

Published: November 08, 2021

Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.

Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.

Journal: Dermatologic therapy

Published: October 27, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026